| Nov 12 |
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Fate Therapeutics: Q3 Earnings Snapshot
|
| Nov 12 |
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
|
| Nov 9 |
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
|
| Nov 8 |
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
|
| Nov 4 |
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 12 |
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
|
| Sep 12 |
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
|
| Aug 22 |
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher
|
| Aug 16 |
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
|
